23.04.2018 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius


 
DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions/Legal Matter Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius 23-Apr-2018 / 16:53 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius Akorn, Inc. filed a lawsuit today against Fresenius at the Court of Chancery in Delaware, USA, for the consummation of the merger agreement. Akorn, Inc. argues that Fresenius was obliged to close the transaction because all closing conditions of the merger agreement, except FTC clearance, were met. Fresenius believes that the lawsuit is without foundation, because Akorn failed to fulfill several closing conditions. Among others, Fresenius' independent investigation found material breaches of FDA1 data integrity requirements relating to Akorn's operations. Fresenius will take all necessary and appropriate measures to vigorously contest the claims. Fresenius does not intend to provide further updates as the lawsuit proceeds. 1 FDA: Food and Drug Administration Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board Bad Homburg v.d.H., April 23, 2018 ---------------------------------------- Contact: Markus Georgi Senior Vice President Investor Relations T: +49 (0) 6172 608-2485 [email protected] ---------------------------------------- End of note --------------------------------------------------------------------------- 23-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604, DE000A2DANS3 WKN: 578560 , A2DANS Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxemburg End of Announcement DGAP News Service --------------------------------------------------------------------------- 677783 23-Apr-2018 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 29.083,00 33.530,00 35.409,00 37.250,00 36.277,00 38.090,00 0,00
EBITDA1,2 5.500,00 6.267,00 6.032,00 7.083,00 7.132,00 0,00 0,00
EBITDA-Marge3 18,91 18,69 17,04 19,01 19,66 0,00 0,00
EBIT1,4 4.327,00 4.589,00 5.251,00 4.631,00 4.385,00 0,00 0,00
EBIT-Marge5 14,88 13,69 14,83 12,43 12,09 0,00 0,00
Jahresüberschuss1 2.676,00 1.816,00 1.871,00 1.915,00 2.823,00 2.960,00 0,00
Netto-Marge6 9,20 5,42 5,28 5,14 7,78 7,77 0,00
Cashflow1,7 3.574,00 3.937,00 3.742,00 4.263,00 6.549,00 0,00 0,00
Ergebnis je Aktie8 2,83 3,25 3,37 3,44 3,06 3,25 3,60
Dividende8 0,62 0,75 0,80 0,84 0,88 0,92 0,96
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

XETR:FRE Charts by TradingView (c)


INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 36,970 Kaufen 20.647,82
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
9,48 17,45 0,55 13,41
KBV KCV KUV EV/EBITDA
1,16 3,15 0,57 6,27
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,88 0,92 2,49 13.05.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
04.05.2022 02.08.2022 02.11.2021 22.02.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,15% -10,07% 4,44% -3,25%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei DGAP abrufen


Medtech , 578560 , FRE , XETR:FRE